The achievement represents progress for the collaboration, which was launched in September 2010 to develop G protein coupled receptor (GPCR)-targeted therapeutic compounds utilizing Anchor’s proprietary pepducin technology. Pepducins
Revolutions Medical said that the capacity can be increased to 20 million syringes per month, and shipments will begin by July 2011. The agreement extends the company’s relationship
ASCENTA 4.0 integrates two generations of gene expression content on the Affymetrix platform into one easy-to-use application, the company said. It features enhancements such as Gene Ontology view
SOHM said that the promotion of Shah will be effective on 15 January 2011. Shah said that they are creating new opportunities for partnerships and joint ventures with
As part of the transaction, Bolh will join the AHS management team as senior vice president, bringing in more than 30 years of experience in clinical and management
The trial designed to get pharmacokinetics and pharmacodynamics as well as safety and efficacy data by demonstrating bioequivalence of the product. Sandoz said that the previous data suggested
As per the terms of the agreement, Amgen has given AMG 108 development rights to MedImmune worldwide, outside Japan. The tie up allows Amgen to get upfront payment,
Sucampo Pharma and Takeda are expecting to recruit around 420 patients in 140 sites in US and Europe. In the trial, the patients will be randomized to receive
The acquisition in Serbia strengthens Azelis’ position in the region, as Finkochem is the second largest distributor in the country. Azelis will now be able to accelerate growth
The facility, which is expected to be operational in the fourth quarter of next financial year, will have facilities such as process chemistry labs, oncology chemical labs, formulation
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.